July 2018 in “International journal of research - granthaalayah” Croton tiglium application significantly improved hair regrowth in alopecia areata patients.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
Baricitinib may not always prevent relapse in alopecia areata.
September 2023 in “SKIN The Journal of Cutaneous Medicine” Talquetamab may cause hair loss and skin issues.
March 2023 in “Jurnal Ilmiah Medicamento” The hair tonic from Usada Bali plants increased hair growth without irritating the skin.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
1 citations
,
September 2024 in “International Journal of Advanced Multidisciplinary Research and Studies” Chemotherapy with carboplatin-paclitaxel causes hair loss in all patients.
11 citations
,
February 2018 in “Medical science monitor” An alternating inflatable head pad reduced pressure ulcers and hair loss in heart surgery patients.
July 2017 in “Journal of Ayurveda and Integrated Medical Sciences” Ayurvedic treatments effectively and permanently treated hair loss in a week.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
July 2025 in “Journal of Integrated Health Sciences” Ayurvedic treatment effectively improved patchy hair loss using simple, cost-effective methods.
Baricitinib shows promise for treating alopecia areata with mild side effects.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
43 citations
,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
May 2020 in “JAAD case reports” Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.
December 2025 in “Journal of Pharmacy And Bioallied Sciences” Personalized Ayurvedic treatment can effectively regrow hair in androgenetic alopecia.
13 citations
,
September 2018 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
2 citations
,
February 2021 in “PubMed” Koilonychia in alopecia areata can improve with oral corticosteroids.
2 citations
,
October 2022 in “Skin appendage disorders” Activated and non-activated PRP are equally safe and effective for treating alopecia areata.
1 citations
,
February 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” April 2026 in “Zenodo (CERN European Organization for Nuclear Research)”
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
13 citations
,
April 2020 in “European Journal of Dermatology” Apremilast showed mixed results for treating severe alopecia areata.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
Bhallatak may help manage diabetes by lowering blood sugar and improving metabolism.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.